Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induced pluripotent stem cell derived allogeneic cellular therapies - RxCell

Next Previous
X
Search
Drug Profile

Induced pluripotent stem cell derived allogeneic cellular therapies - RxCell

Alternative Names: Allogeneic cellular therapy - RxCell; iPSC-derived-cellular-therapies - RxCell

Latest Information Update: 07 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Molecular and Cell Biology; National University of Singapore; RxCell; Singapore Eye Research Institute
  • Class Induced pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 05 Dec 2023 Preclinical trials in Age-related macular degeneration in USA (Parenteral)
  • 05 Dec 2023 RxCell plans a phase I/IIa trial in age-related macular degeneration in USA (Parenteral)
  • 26 Oct 2021 RxCell plans a first-in-human trial for Age-related macular degeneration in Singapore

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top